Press Releases

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Jul 08, 2021

AVROBIO to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 10, 2021-- AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present at the JMP Securities Life

Jun 10, 2021

AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a non-statutory stock option for the purchase of up to an

Jun 04, 2021

AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update

Held meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for AVR-RD-01 for Fabry disease Dosing completion in ongoing FAB-GT Phase 2 trial reaches 50%, with three additional patients dosed in three months CAMBRIDGE, Mass.

May 13, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

May 06, 2021

AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

Anticipates initiating registration trial with kidney biopsy endpoint in mid-2022 to support potential full approval of AVR-RD-01 as first-line therapy, subject to FDA discussion and agreement Two additional patients dosed in last two months in ongoing FAB-GT Phase 2 trial; plan to enroll a total

May 03, 2021

AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 27, 2021-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that two oral presentations and two posters featuring data from its pipeline of

Apr 27, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 6, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Apr 06, 2021

AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

100% kidney substrate reduction at 12 months post-gene therapy in the first patient dosed with the plato ® gene therapy platform in FAB-GT 1 trial for Fabry disease One new patient dosed and three new patients enrolled in Fabry disease clinical trial since January 2021 Orphan drug designation

Mar 18, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Mar 05, 2021



Displaying 1 - 10 of 19

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.